S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
NASDAQ:CELC

Celcuity Stock Forecast, Price & News

$11.00
-0.48 (-4.18%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.44
$11.64
50-Day Range
$11.00
$18.34
52-Week Range
$10.44
$33.01
Volume
49,153 shs
Average Volume
33,072 shs
Market Capitalization
$164.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.47
30 days | 90 days | 365 days | Advanced Chart
Receive CELC News and Ratings via Email

Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter.


Celcuity logo

About Celcuity

Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CELC
Fax
N/A
Employees
30
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.14 per share

Profitability

Net Income
$-9.47 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
9,366,000
Market Cap
$164.05 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/07/2021
Today
1/21/2022
Next Earnings (Estimated)
2/15/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.08 out of 5 stars

Medical Sector

539th out of 1,418 stocks

Medical Laboratories Industry

13th out of 31 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












Celcuity (NASDAQ:CELC) Frequently Asked Questions

Is Celcuity a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Celcuity stock.
View analyst ratings for Celcuity
or view top-rated stocks.

How has Celcuity's stock price been impacted by COVID-19?

Celcuity's stock was trading at $7.12 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CELC stock has increased by 54.5% and is now trading at $11.00.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Celcuity?

Celcuity saw a decrease in short interest in December. As of December 15th, there was short interest totaling 175,000 shares, a decrease of 17.9% from the November 30th total of 213,100 shares. Based on an average daily volume of 45,900 shares, the days-to-cover ratio is presently 3.8 days. Currently, 2.4% of the shares of the stock are short sold.
View Celcuity's Short Interest
.

When is Celcuity's next earnings date?

Celcuity is scheduled to release its next quarterly earnings announcement on Tuesday, February 15th 2022.
View our earnings forecast for Celcuity
.

How were Celcuity's earnings last quarter?

Celcuity Inc. (NASDAQ:CELC) announced its earnings results on Sunday, November, 7th. The company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.10. During the same period in the previous year, the firm earned ($0.24) earnings per share.
View Celcuity's earnings history
.

What price target have analysts set for CELC?

5 equities research analysts have issued 1-year price targets for Celcuity's shares. Their forecasts range from $24.00 to $50.00. On average, they anticipate Celcuity's stock price to reach $38.00 in the next year. This suggests a possible upside of 245.5% from the stock's current price.
View analysts' price targets for Celcuity
or view top-rated stocks among Wall Street analysts.

Who are Celcuity's key executives?

Celcuity's management team includes the following people:
  • Brian F. Sullivan, Chairman & Chief Executive Officer
  • Vicky Hahne, Chief Financial Officer
  • Lance G. Laing, Secretary, Director & Chief Science Officer
  • Arthur P. DeCillis, Chief Medical Officer
  • Sheri Smith, Head-Clinical Operations

What other stocks do shareholders of Celcuity own?

When did Celcuity IPO?

(CELC) raised $18 million in an IPO on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

What is Celcuity's stock symbol?

Celcuity trades on the NASDAQ under the ticker symbol "CELC."

How do I buy shares of Celcuity?

Shares of CELC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celcuity's stock price today?

One share of CELC stock can currently be purchased for approximately $11.00.

How much money does Celcuity make?

Celcuity has a market capitalization of $164.05 million. The company earns $-9.47 million in net income (profit) each year or ($2.02) on an earnings per share basis.

How many employees does Celcuity have?

Celcuity employs 30 workers across the globe.

What is Celcuity's official website?

The official website for Celcuity is www.celcuity.com.

Where are Celcuity's headquarters?

How can I contact Celcuity?

Celcuity's mailing address is 16305 36TH AVENUE NORTH SUITE 100, MINNEAPOLIS MN, 55446. The company can be reached via phone at (763) 392-0767.


This page was last updated on 1/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.